HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sharpe, S. Articles by Cranage, M. Search for Related Content PubMed PubMed Citation Articles by Sharpe, S. Articles by Cranage, M. Agricola Articles by Sharpe, S. Articles by Cranage, M.

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity

Tomá Hanke³

Centre for Applied Microbiology and Research (CAMR), Salisbury SP4 0JG, UK¹
Institut für Molekulare Virologie, GSF-Forschungszentrum für Umwelt und Gesundheit GmbH, Ingolstädter Landstr. 1, 85764 München-Neuherberg, Germany²
MRC Human Immunology Unit, Institute of Molecular Medicine, Oxford OX3 9DS, UK³
Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA⁴

Author for correspondence: Sally Sharpe. Fax +44 1980 611310. e-mail sally.sharpe{at}camr.org.uk

A major aim in AIDS vaccine development is the definition of strategies to stimulate strong and durable cytotoxic T lymphocyte (CTL) responses. Here we report that simian immunodeficiency virus (SIV)-specific CTL developed in 4/4 macaques following a single intramuscular injection of modified vaccinia virus Ankara (MVA) constructs expressing both structural and regulatory/accessory genes of SIV. In two animals Nef-specific responses persisted, but other responses diminished and new responses were not revealed, following further vaccination. Vaccination of another two macaques, expressing Mamu A*01 MHC class I, with MVA constructs containing nef and gag–pol under the control of the moderate strength natural vaccinia virus early/late promoter P7.5, again induced an early Nef-specific response, whereas responses to Gag remained undetectable. Anti-vector immunity induced by this immunization was shown to prevent the efficient stimulation of CTL directed to the cognate Gag epitope, p11C C-M, following vaccination with another MVA construct expressing SIV Gag–Pol under a strong synthetic vaccinia virus-specific promoter. In contrast, vaccination of a previously unexposed animal resulted in a SIV-specific CTL response widely disseminated in lymphoid tissues including lymph nodes associated with the rectal and genital routes of SIV entry. Thus, despite the highly attenuated nature of MVA, repeated immunization may elicit sufficient anti-vector immunity to limit the effectiveness of later vaccination.

This article has been cited by other articles:

				A.-H. Hovav, M. W. Panas, C. E. Osuna, M. J. Cayabyab, P. Autissier, and N. L. Letvin The Impact of a Boosting Immunogen on the Differentiation of Secondary Memory CD8+ T Cells J. Virol., December 1, 2007; 81(23): 12793 - 12802. [Abstract] [Full Text] [PDF]

				J. M. DiNapoli, A. Kotelkin, L. Yang, S. Elankumaran, B. R. Murphy, S. K. Samal, P. L. Collins, and A. Bukreyev Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens PNAS, June 5, 2007; 104(23): 9788 - 9793. [Abstract] [Full Text] [PDF]

				G. Koopman, D. Mortier, S. Hofman, H. Niphuis, Z. Fagrouch, S. Norley, G. Sutter, P. Liljestrom, and J. L. Heeney Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens J. Gen. Virol., October 1, 2004; 85(10): 2915 - 2924. [Abstract] [Full Text] [PDF]

				M. J. Palmowski, L. Lopes, Y. Ikeda, M. Salio, V. Cerundolo, and M. K. Collins Intravenous Injection of a Lentiviral Vector Encoding NY-ESO-1 Induces an Effective CTL Response J. Immunol., February 1, 2004; 172(3): 1582 - 1587. [Abstract] [Full Text] [PDF]

				J. W. Hodge, D. J. Poole, W. M. Aarts, A. Gomez Yafal, L. Gritz, and J. Schlom Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses Cancer Res., November 15, 2003; 63(22): 7942 - 7949. [Abstract] [Full Text] [PDF]

				T. Fischer, O. Planz, L. Stitz, and H.-J. Rziha Novel Recombinant Parapoxvirus Vectors Induce Protective Humoral and Cellular Immunity against Lethal Herpesvirus Challenge Infection in Mice J. Virol., September 1, 2003; 77(17): 9312 - 9323. [Abstract] [Full Text] [PDF]

				T. J. Harvey, I. Anraku, R. Linedale, D. Harrich, J. Mackenzie, A. Suhrbier, and A. A. Khromykh Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development J. Virol., July 15, 2003; 77(14): 7796 - 7803. [Abstract] [Full Text] [PDF]

				T. Woodberry, J. Gardner, S. L. Elliott, S. Leyrer, D. M. Purdie, P. Chaplin, and A. Suhrbier Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias J. Immunol., March 1, 2003; 170(5): 2599 - 2604. [Abstract] [Full Text] [PDF]